A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.

Next Previous
Trial Profile

A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Vistusertib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 5 Jun 2017 to 12 Dec 2017.
    • 07 Jun 2016 Results (n=99) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 25 Apr 2016 Planned End Date changed from 1 Aug 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top